Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

Merck announces Health Canada approval of Brenzys® for indications

Sep 15, 2020

Merck announced Health Canada has approved Brenzys® (biosimilar etanercept) for four new indications:

  • adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy

  • pediatric patients ages 4 to 17 years with chronic severe PsO who are candidates for systemic therapy or phototherapy

  • reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis and improving physical function in adult patients with psoriatic arthritis (PsA)

  • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years

Print Page Mail Article